Radiation therapy has been used for decades for patients with prostate cancer. The clinical results from IMRT have shown that even higher doses of radiation are needed, especially for patients with intermediate risks and high risk prostate cancers.
Dr. Katz examines how CyberKnife stereotactic radiosurgery capitalizes on the major breakthrough in prostate cancer radio-biology. That major breakthrough is the fact that fewer, larger doses of radiation can better treat prostate cancers, while limiting side effects even further than IMRT.
Yes, it's true- 1 week of CyberKnife is better than 8-9 weeks of IMRT. Learn why Dr. Katz agrees here
"I built my practice on basic American business principles. Better, Quicker, Cheaper. The CyberKnife delivers better cures with fewer side effects. The CyberKnife is quicker with only one week of treatment instead of 8-9 weeks. Therefore it is cheaper for both the patient and the insurance company" states Dr. Ed Hughes. This comparison study supports his mission. Learn how here.
In 2011 Dr. Debra Freeman and Dr. Christopher King published “Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes”. Not only did these prostate cancer specialists focus on the outcomes of reduced urinary incontinence and rectal toxicity, they also discussed better biochemical disease-free survival (bDFS) rates. Ultimately, survival rates are the most important result of quality cancer care. The following chart compares the different treatments offered for prostate cancer and these survival rates at the 5 year mark. Read the study to learn more here.
In 2012, Dr. Alan Katz, a noted CyberKnife specialist, published a comparison of the quality of life after stereotactic radiosurgery versus prostatectomy-both nerve sparing and non-never sparing.
The key finding was that patients who underwent surgery had more long term urinary side effects and more impotence than those patients treated with CyberKnife. Yet the long term bowel side effects, though initially worse with CyberKnife treatment, were the same as surgery in the long term. Since this study was conducted, First Dayton CyberKnife has found ways to reduce these bowel effects through improved treatment planning.
Learn other improvements to prostate cancer patients Quality of Life here.
©2017 First Dayton CyberKnife
937-293-2273 | 2632 Woodman Center Court | Dayton, OH 45420
Site design by Edison Lightworks, LLC